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1 Introduction
Respiratory mucosa of nose and paranasal sinuses are
subject of daily routine of the ENT specialist. Restoration
oftherespiratoryfunctionistheaimofbothconservative
and surgical therapies. Therefore, the role of respiratory
mucosa has been put into the centre of this paper. For
ventilation aspects, it is referred to the article of
Lindemann and Keck. From the perspective of clinical
relevance, profound knowledge and innovative research
resultsregardinganatomy(withembryology),physiological
functions and their diagnostic tests are presented. Due
totheamountofdifferentpathophysiologies,onlyselect-
eddisordersaresummarisedwithregardtotheirimpaired
functionoftherespiratorymucosaandtherapystrategies
are outlined. To facilitate coherent reading, references
to the more surgically orientated papers are included.
2 Embryology
During the 6
th week of embryological development, ecto-
dermal thickened parts of the frontobasal prominence
invaginate resulting in two symmetrical nasal placodes.
Nasalpitsdividetheplacodes(Foveanasalis)intomedial
and lateral nasal processes [1]. This deepens, becoming
the nasal sac – an ectodermally lined cavity, which is di-
vided into two halves by the primary septum. Between
weeks 6 and 7, a membrane separates the oral cavity
fromtheprimitivechoanae.Thisresolvesduetoimmigra-
tion of mesenchymal cells. The mesenchymal septum
(secondary septum) grows caudally, merging with the
palate and enlarging the embryonic structures of the
nose. In weeks 7 and 8, first cartilaginous cells are iden-
tified, including parts of the turbinates. Starting in the
3
rd month, mucosal lining migrates into the lateral nasal
wall priming the development of the paranasal sinuses.
By cell differentiation and maturation of the respiratory
mucosa, detection of glands is possible after the 4
th
monthof intrauterinedevelopment.Duringthe 5
th month
of fetal development, ossification of the nose starts, in-
cluding the previously cartilaginous areas of the turbin-
ates.Influencedbyvarioustranscriptionalfactors,includ-
ing Sox [2], cells differentiate further into the various cell
types included in respiratory mucosa. For ciliogenesis
and their pathophysiologies, several influencing factors
play their part to a certain extent [3]. In animal models,
the regulation of ciliogenesis is proven for FoxJ1,
TTC25-GFP, Mig12-GFP, OFD 1, Ftm and Talpid3 [4], [5],
[6]. Deletion of Talpid3, which works via the hedgehog
signaling pathway, will inhibit the development of cilia
completely[6],whiledisordersofthetohedgehogsignal-
ingpathwayaloneresultinabnormalordegeneratedcilia.
A specific disruption of Talpid3 has been suggested as
animalmodelforprimaryciliarydyskinesiawithpolycystic
kidneys[6].Foranchorageandorientationofcilia,further
factors have been identified, such as FoxJ1 [4].
3 Anatomical and histological
structures of the respiratory
mucosa
Dorsally to the vestibulum nasi, which is lined with
squamousepithelium,liesthenasalcavity.Thisiscoated
with 120 cm
2 of pseudostratified columnar ciliated epi-
thelium. The respiratory mucosa shows a thickness of
0.3–5 mm. Three (rarely four) turbinates protrude into
the nasal cavity showing the thickest respiratory mucosa
on their medial surface. In respiratory mucosa, several
specificcelltypes canbeidentified.Allcellsareattached
onthebasalmembrane.Basalcellslieonthemembrane
and show non contact with the epithelial surface. Their
specific morphologic features are desmosomes for cell
adhesion.
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andhave300–400microvilliontheirsurface.Thegeneral
principle of microvilli is the increase in surface area to
retain moisture and to prevent drying of the surface [7].
Another 20–50% of epithelial cells are ciliated cell pos-
sessing 200–300 cilia on their surface, which are the
morphological substrate of the mucociliary clearance.
Cilia are 5 to 10 µm long and 250 nm thick and sheated
in a plasma membrane. Within cilia, nine double tubules
are arranged around two sheated central tubules. An in-
ner sheath surrounds the central tubules. Outer pairs of
microtubules (A and B-tubules) are connected to each
otherbynexinbridgesanddyneinarmsandtothecentral
pair by radial spokes. Bending of the cilia occurs as an
ATP-consuming mechanism, called “sliding filament
mechanism”. Existence of non-motile cilia is discussed
in cells without central double tubules acting as sensory
antenna. Cilia are covered by a 10–15 µm thick layer of
mucus, filling also the spaces between cilia [8]. In respi-
ratory mucosa, goblet cells and seromucous glands in
theadjacentconnectivetissuearetypicallyfound. Goblet
cells represent 5–15% of cells in the respiratory mucosa
andproducesecretionsfortheendonasalmucustogether
withthesubmucosalglands.Nexttotheirform,existence
of microvilli and a small opening, called stoma, are their
characteristics.Theydifferentiateoutofnon-ciliatedcells
[9]. In connective tissue, 20–80 anterior serous glands
with 2–20 mm long ducts opening into small crypts are
visible. Their importance is unclear [10]. About 90,000
seromucous glands possess ducts lined by cubical epi-
theliumandareorganisedintwolayers.Moreover,20–50
intraepithelial mucous glands are detected around a
central lumen. Their contribution to mucus production is
regarded as small.
At the anterior septum, epithelium is underlined by a
1.5 mm thick tissue of convoluted vessels, called Locus
Kieselbachii. In addition, venous plexus are seen in the
areaoftheinferiorturbinateandthenasalseptum,acting
as swell bodies during the nasal cycle.
Dimensional orientation for healthy respiratory mucosa
inabiopsyindicateasubepithelialcapillarynetworkwith
a diameter of 0.025 mm, below a 1.6–10 µm thick basal
membrane covered with a epithelium showing 40–100
µm height. Ciliated cells have a height of 15–20 µm and
a width of 15 µm. Human cilia are about 6 µm long and
0.3 µm thick. Microvilli are 0.5–4 µm long and about 0.1
µm thick. These reference data are limited due to a high
degreeofvariationdependingontheendonasallocalisa-
tion of cells.
Asmigratingcells,moreT-thanB-lymphocytesaredetect-
able in subepithelial healthy tissue. The ratio of T-helper
to regulatory T-cells (T-suppressor cells) is subepithelial
3:1 and in deeper layers 2:1 [11]. Natural killer cells are
rare. 50% of IL-5-positive cells and 100% of IL-6 positive
cells are mast cells [12].
3.1 Vascular supply
Branches of the maxillary artery are responsible for the
arterial supply, including the sphenopalatine artery, the
posterior lateral nasal artery and the infraorbital artery.
Venous blood drainage occurs along the facial vein after
unification of the supratrochlear and supraorbital veins.
3.2 Lymphatic vessels
Superficialanddeeplymphaticvessels(15–200µm)can
be demonstrated in respiratory mucosa, which lead in
the middle nasal meatus to the natural ostium of the
maxillary sinus. Their density decreases from top to bot-
tom of the middle nasal meatus; their number is higher
in the paranasal sinuses than the nose. Several connec-
tions are visible between lymphatic vessels and the vas-
cular supply [13]. More lymphatic vessels begin at the
nasalfloorand the turbinates and converge in the medal
inferior area of the turbinates. From this area, lymphatic
vesselspassretropharyngeallyandtotheparapharyngeal
space, reaching lymph nodes of both anatomic areas
[14].
3.3 Innervation und regulation
Autonomic innervation takes place via the posterior eth-
moidal nerve. Sympathetic innervation of the nasal mu-
cosa is supplied via branches of the superior cervical
ganglion passing along with the nerve of the pterygoid
canal [15]. Hypothalamic stimulation will provoke a
vasoconstriction [16]. Glands of the nasal mucosa, as
well as the vessels, have a direct parasympathetic inner-
vation leading to direct parasympathetic increase of
nasal secretions via transsudation and exsudation [17].
Variouscotransmittersweredetectedinnasalrespiratory
mucosa [18]. Parasympathetic neurons have mostly
vasointestinal peptide (VIP) as cotransmitter to acetyl-
choline [19]. VIP is stimulating secretions (more serous
thanmucous)andvasodilatatingatarterialandsinusoidal
vessels[20].Sympatheticneuronscontainneuropeptide
Y (NPY) as key cotransmitter to noradernaline and inner-
vate predominantly arterioles and arteriovenous anasto-
moses. Liberation of NPY results in prolonged vasocon-
striction,togetherwithdecongestionofvenoussinusoidal
vessels [21]. Substance P acts as Co-transmitter for
Neurokinin A [22] and Calcitonin Gene-Related Peptide
(CGRP) at arteries. The high number of cotransmitters is
regardedasapossibilitytoadjustcongestionofthenose
delicately.Itsdisturbancemaycontributetotheaetiology
of various, non-allergic rhinitis disorders [23].
An additionalway of regulationis providedby endothelial
nitricoxidesynthase(NO-Synthetase;NOS;producingNO
in the tissue) located in capillaries and arterioles near
glands and nerve fibres around seromucous glands. As
cotransmitterinparasympatheticnervefibres,nitricoxide
(NO) shows a neuromodulating and vasodilatating effect
stimulating also seromucous glands [24]. As a con-
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degree of endonasal congestion can be altered [24].
4Physiologyofrespiratorymucosa
Every day about 12,000 litre airflow is passing through
the adult nose [25] and being hydrated (cf. article of
LindemannandKeckhttp://www.egms.de/en/journals/
cto/2011-9/cto000072.shtml) and filtered. The nose is
of extreme importance to protect the distal airways from
deterious influence of gas, aerosol and pathogens. The
nose and paranasal sinuses also act as area of voice
resonance and produce nitric oxide (NO) for regulation
oflowerairways.Finally,thenoseactsaschemosensoric
organ responsible for smelling.
4.1 Cleaning function
Thenasalpassagefilters95%ofparticleswithadiameter
of more than 15 µm out of inspired air [25]. The cleaning
function for pollen and dust of smaller dimensions is
severely diminished but not abolished [26]. Liquids in-
haledasaerosolwillbeeliminatedfromtheupperairway
if inspirited through the nose to 95% (mouth: 50%).
Dosageofinhaledgasmeasuredinthepulmonaryalveoli
will be diminished from 6–10% during mouth breathing
to 0.9% during nasal breathing [27].
4.1.1 Sneeze reflex
Sneezing aims for elimination of particles from the nose.
This reflex is most complexly coordinated affecting also
the solitary nucleus [28]. Typically, sneezing will be pro-
voked by foreign bodies in the anterior parts of the nose,
which stimulate H1-receptors of trigeminal C-fibres [29].
After inspiration [30] ceases to allow glottic closure,
sudden contraction of abdominal and breast muscles
happens. After glottal opening, liquid drops or foreign
bodies are tossed from the nose at velocities of 50 m/s
[31]. This type of reflex can be triggered by light called
photic sneeze reflex.
4.1.2 Nasolacrimal reflex
Nasolacrimal reflex results after chemical or mechanical
stimulation of the nasal respiratory mucosa in increased
lacrimal secretion. Afferent, C-fibre nociceptive neurons
run together with the trigeminal nerve to the superior
salivary nucleus, continuing via the geniculate ganglion,
the large superficial petrosal nerve and through the
pterygoidcanaltothesphenopalatineganglion.Choliner-
gic fibres reach together with the maxillary nerve the
lacrimal gland [29]. Stimulation of one side leads also to
a physiological, weaker reaction contralaterally [28] (for
more information regarding reflexes: [32]).
4.2 Unspecific defense mechanism
Staticanddynamicmechanisms(structureoftheepithe-
lium, configuration of endonasal airflow) and regulated
physicalandchemicalmechanisms(structureandcontent
of nasal mucus, mucociliary clearance, nasal cycle,
plasma extravasation by NO [33]) assist in immune de-
fense. Epithelial cells have a key position as a physical
barrier and are the mainly responsiblecells for maintain-
ing the mucociliary transport. Respiratory mucosa of the
nose is characterised by a high enzymatic activity, espe-
ciallyofthecytochromeP450system[34].NO,produced
mainly by the mucosa of the sinuses and released at the
surface, is discussed to have bactericidal effects in the
airway [35].
4.2.1 Mucociliary clearance (MCC)
Mucociliaryclearanceisdefinedascleaningofupperand
lower airway by interaction of nasal mucus (about 200 g
or 2 litre/day produced by the respiratory mucosa) [36]
and ciliary beating. Number, structure and coordinated
stroke of the cilia are as important as the biochemical,
physical and chemical properties of the mucus. Nasal
mucus has a weak, flexible, three-dimensional network
formed from linear, hydrated mucin molecules. This is
enhanced by disulfide bonds and secondary chemical
connections between ions [37]. To prevent infections,
mucus is slightly acid with a physiological pH-value of
5.5–6.5 andhas a smallcapacityas chemicalbuffer. Via
hydroxyl- (OH-) groups and oligosaccharide chains, nega-
tively charged groups, the highly hydrated form of nasal
mucus and the embedded network of linear and flexible
glycoproteins, nasal mucus may form unspecific second-
aryconnections,e.g.withpathogensordrugs.Viscoelasti-
city, adhesive and cohesive properties of nasal mucus
are mainly determined by the glycoprotein compound
[37]:Theycompriseaproteinbackbonecovalentlybound
to oligosaccharide chains at a molecular mass of about
200Kilodalton(kDa)andareresponsibleforthenegative
electric charge of the nasal mucus.
Optimalmucociliaryclearanceisachievedat37°Celsius
and 100% relative humidity (absolute: 44 mg/dm
3).
Nasal Mucus is about 10–15 µm thick [38] and has two
layers: the lower, 6 µm thick liquid layer (also called:
periciliary liquid) is covered by the more viscous gel
phase. The gel phase is structured by embedded mucin.
Height of the liquid layers has tremendous effect of the
efficiencyoftheciliarystroke[39].Nasalmucuscontains
90% water and glycoproteins as well as ions (cf. Table 1).
Itisproducedbysubmucosal,seromucousglands,goblet
cells,transsudationofbloodplasma,mucosaltissuefluid
and tear fluid. Due to transsudate, most proteins detect-
able in serum may also be demonstrated in nasal secre-
tions. In cases of local inflammation, the amount of
transsudate and their respective proteins will increase.
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Table 1: Concentration of ions in the nasal mucus [36]
Due to the coordinated, metachronous ciliary stroke (cf.
Figure 1), the mucus layer will be moved at a velocity of
2–25 mm/min [40]. In detail, control of the ciliary beat
frequency is unknown. However, ciliary beat frequency
will increase if cells are exposed to NO or a mechanical,
calcium-mediated stimulus [41], whereas IL-13 will de-
crease the frequency [42]. In addition, intensive physical
activity will decrease mucociliary clearance [43].
Particles bound to the mucus layer will be transported
towards the pharynx passing the hiatus semilunaris. A
second stream runs from the sphenoid sinus to the pos-
terior ethmoid towards the choanae. Within a paranasal
sinus, mucociliary clearance will always be orientated
towardstheprimarynaturalopening[44],whileaccessory
ostia are bypassed by the mucociliary clearance.
Next to water and electrolytes, immune globulin (Ig) G
and A can be detected in high concentrations in nasal
mucus. Secretoric Ig-A (up to 80% Ig-A1; among others
againstCoxsackievirusesandpoliovirus)isanobligatory
ingredientandmay provideup to 50% ofthetotalprotein
ofnasalsecretions[45].Itissecretedintothetissuefrom
plasma cells located near the basal membrane of the
glands to bind and neutralise the antigen. Due to this ef-
fect,Ig-Aisdiscussedasanimportantfactorinpathogenic
microbiological colonisation of respiratory mucosa.
Ig-G is synthesised in nasal submucosa and secreted
aftermuscarinergicstimulationorexpositiontohistamine
[46].Inphysiology,Ig-Misnotdetectable,whileIg-Elevels
are below serum concentration. Moreover, lipids (e.g.
surfactant [0.8%] and carboanhydrase [1%]) may be de-
tected.
Applicationofsodium-chlorideleadstoincreaseofciliary
beat frequency [47] and thereby improvement of muco-
ciliary clearance. According to a Cochrane review [48],
salt concentration is of minor importance. On the other
hand – depending on the pathophysiology – hypertonic
solutions in chronic rhinosinusitis and isotonic salty
solutions in acute sinusitis may be beneficial [49].
4.3 Humoral mechanisms
Unspecific substancesfor immunedefensearelocalised
in the epithelium and in nasal secretions. These include
lysozyme (attacks peptidoglykans in the cell wall of gram
positive bacteria), lactoferrin (inhibits bacterial growth)
[50] and oligosaccharides (bind bacteria) [51]. Further-
more, neutrophil granulocytes produce proteases and
hydrolases to destroy the cell membrane of bacteria and
viruses. The 20 proteins of the complement system are
detectable in blood and in tissue. They destroy foreign
structures and marker pathogens for phagocytosis. The
kinin-kallikrein system activates an inflammatory re-
sponseafterviralinvasionbyvasodilatation.Intracellular
interferon impedes viral replication and inhibits ongoing
viral infection.
4.4 Cellular mechanisms
Neutrophil granulocytes, monocytes and macrophages
are cellular components of the host defense using
phagocytosis in the subepithelial tissue of the nose and
sinuses. Immigrated natural killer cells destroy infected
cells.Underphysiologicconditions,importanceofcellular
mechanisms is subordinated to unspecific components
of immune defense. In case of pathogen invasion, mul-
tiple immunocompetent cells immigrate, and increase
the importance of cellular defense. The specific immune
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Table 3: Normal microbiological findings in the nose of children
systeminnasalrespiratorymucosaispartofthelymphat-
ic system (mucosa-associated lymphatic tissue; MALT).
4.5 Nasal cycle
Nasal cycle is defined as spontaneous and reciprocal
change of nasal congestion without change of the total
nasal airflow. It was first described by R. Kayser in 1895
[52]. According to literature, nasal cycle can be detected
in 70–90% of humans [53], [54].
The nasal cycle is regulated by the hypothalamus [55],
withefferentsrunningalongthevidiannerveandshowing
an asymmetrical activity in controls [56]. Changes of
volume in the erectile tissue of the septum, the inferior
andmiddleturbinatesandevenintheparanasalsinuses
can be demonstrated [57].
The working and resting phase can be easily distin-
guished. During the working phase the nasal passage is
characterised by an increased hydraulic diameter, pas-
sage of nasal airflow and turbulence, while resistance is
decreased. During resting phase resistance is raised,
while hydraulic diameter, transnasal airflow and turbu-
lence are diminished [53]. Mucociliary clearance is en-
hanced by factor 2.5 in a working phase in comparison
to the contralateral resting phase [58]. Resting phase
allowsgatheringofmucosalmoisture[59],[60].Mucosal
cleaning and regeneration as well as improved host de-
fense are discussed as advantageous during the evolu-
tion, eventually leading to the development of the nasal
cycle [61].
Ifanalysedmoreclosely,contralateralworkingandresting
phaseswithregularchange('classicaltype')canbediffer-
entiated from parallel working and resting phases ('in-
concerttype')andundefinedphases('irregulartype').The
frequencyofnasalcyclephaseclassifiedasclassicaltype
decreases with age [62]. There is a high amount of vari-
ation in the duration of phases reported (duration of
phase:1.6h[54]1–2.5h[63];1.5–10h[64];2.5h[65],
2.9 h [66], 3–4 h [67]; 3–5 h [68]; 4.3 h [69]; 1–5–10
h [53]; 7 h [70]). A relationship to the individual duration
of rapid eye movements (REM) in sleep has been
demonstrated [71].
The change from one phase to another happens quite
rapidlywithinafewminutes.Thisishelpfulindistinguish-
ing changes of nasal congestion caused by the nasal
cycle from those due to change of body position [68],
[72], [73], [74], or physical activity mediated though the
adrenergic sympathetic system.
4.6 Microbiological colonisation
In the nose, a physiologic, multi-microbial colonisation
exists. Specific articles are summarised in Table 2 and
Table 3. Normal microflora and pathogens are differenti-
ated from each other by their ability to release a Th1/2-
mediated immune reaction. Commensal bacteria may
pass the epithelial barrier and will only evoke a minimal
T-cell activation without effects on regulatory T-cells
(CD25FoxP3) [75].
Paranasalsinusesaresterileunderphysiologicconditions
[76]. In 50 cultures obtained during nasendoscopy of 25
healthy controls, 32 bacteria were detected such as
Staphylococcus aureus, coagulase-negative Staphylo-
cocci,CorynebacteriaandPropionibacteriumacnes[77].
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patientswithclinicallynormalendoscopicfindings.Here,
coagulase-negativeStaphylococci(69%),Corynebacteria
(25%), S. aureus (31%) and Pseudomonas aeruginosa
(3%) canbe identified[78]. Fungusis alsopart ofnormal
microflora of nose and paranasal sinuses. While 20% of
postnatal babies have a positive fungal culture in nasal
secretions, this detection rate increased to 94% at the
age of 4 months [79].
Methodsofchoicetodetectcolonisationareendoscopic-
ally guided aspirate specimens or sinus punctures. In
comparison to the latter, accepted as gold standard,
cultures from the middle nasal meatus showed a sensi-
tivity of 80% and specificity of 100% with regard to their
detection rate (positive predictive value: 100%; negative
predictivevalue78.6%).Ifanalysedprospectively,results
will match in 88.5%, suggesting that endoscopically
guidedaspirationwillbesufficientwhileresultinginminor
burden for the patient [80].
In 70% of people working in a hospital, S. aureus can be
detected in a nasal swab. To facilitate defense of the
respiratorymucosa,exposuretocommensalbacteriahas
been evaluated. Medical doctors may terminate their
colonisation with methicillin-sensitive S. aureus, if inocu-
lated with Corynebacteria spp., also decreasing the risk
of methicillin-resistant S. aureus infection [81].
4.7 Regeneration and wound healing
The detailed sequence of wound healing of the nasal
respiratory mucosa is delicately regulated [82]. In the
following, relevant procedures during course of wound
healing with evident clinical aspects will be presented.
Aim of wound healing is structural and functional repair
of the tissue defect. Fundamental differences between
partial and full-thickness defects (affecting all layers) of
respiratorymucosahavebeenreported[83]:Preservation
of the basal membrane results in rapid restoration of
normal epithelial height [84], while its destruction will
lead to a repair process taking weeks to months [84].
Deeper wounds will also result in scar formation, with its
extent being quite variable [85]. Duration of wound
healing of respiratory mucosa is estimated as 6 months,
and sometimes even longer [86]. Physiological wound
repairhappensindifferentstages,whichmaytemporarily
overlap and macroscopic appearances show fluent
transition. The stages are regulated by a variety of cy-
tokines and growth factors.
4.7.1 Temporal sequence of wound healing
Based on the endoscopic aspect of the wound area, the
stages of blood crusting (until day 10), obstructive
lymphoedema (until day 30), and mesenchymal growth
(up to three months) can be distinguished with sub-
sequent scar formation [87].
Coagulation and haemostasis
The trauma leads to vessel injury and release of blood.
Thrombocytes aggregate and release PDGF (Platelet-de-
rived Growth Factor). In parallel, vasoconstriction occurs
todiminishtheinjuryofthevesselwall.Plateletsactivate
the coagulation cascade to close the defect with a
thrombus [88]. Subsequently, the thrombus dehydrates
and resolves into crusts. Neutrophil granulocytes immi-
grateandreleasepro-inflammatory cytokines.Thisleads
tovasodilatationandincreaseofvesselpermeabilitywith
oedemaformation.Plateletsintegratedintothefibrinnet
chemotactically attract macrophages [89], fibroblasts
and endothelial cells to the defect [90]. Due to repeated
microtraumata,thiscoagulationcascademaybeactivated
on several occasions during the first one to two weeks
[91].
Inflammatory phase
Nexttoneutrophilgranulocytes,thethrombusisdissolved
byimmigratedmonocytesandmacrophages.Neutrophils
release more proliferative cytokines (e.g. Transforming
GrowthFactor(TGF)-α,TGFβ1,IL-1).Cellmigrationshows
a peak for neutrophil granulocytes after 2 days, for
monocytes and macrophages after 4–5 days, and for
lymphocytes after six days. Monocytes differentiate to
tissue macrophages and eliminate microorganisms and
debris. They also regulate enzymatic tissue disaggrega-
tion. Macrophages control the transitionfrom the inflam-
matory to the proliferative phase by production of growth
factors, such as tumor necrosis factor (TNF)-α [90].
Proliferative phase
The defect will be filled with granulation tissue. This
happens by proliferation of connective tissue, with syn-
thesis,degradation,andalterationofcollagen,angiogen-
esis, production of glycosaminoglycans and epithelial
coverage. In addition, osteoneogenesis can be observed
[86], [92], [93]. This phase starts about three days after
the initial trauma and lasts for at least 2–3 weeks.
Fibroblasts produce among other substrates collagens,
a main component of the extracellular matrix (ECM) in
wounds detectable since day three after injury [94]. Col-
lagen bundles are built by rearrangement of collagen
fibril orientation. Due to better organisation of collagen,
resistance of the wound against shear is increased. One
year after injury, remodelling processes of collagen are
still detectable. Due to the close molecular connections
of fibroblasts, ECM and collagen synthesis, fibroblasts
are regarded as main source of adhesions.
As early as 24 hours after epithelial injury [95], epithelial
cells migrate concentrically at a velocity of 20 μm/h [92]
intothedefect[92],[96].Untilepithelialclosure,depend-
ing on the defect’s size more than two weeks will pass
[97].Inparallel,changesinECMproteins,suchasmatrix
metalloproteinases(MMPs)andreleaseofmorecytokines
take place. MMP-9 (see below) is of special interest. Re-
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is detectable after 4–8 weeks [98].
Phase of remodelling
During this phase, granulation tissue is replaced by scar
formation. “Airway remodelling” is frequently used as
generaltermforcontinuousadaptationofmucosaduring
the course of a chronic inflammation (e.g. bronchial
asthma or chronic sinusitis). In contrast, remodelling in
wound healing is defined as a process of collagen degra-
dation, conversion and synthesis and has a limited dura-
tion. Type-3 collagen is replaced by the more firm type-1
collagen. This process starts after 48–72 hours and is
detectable by increased rate of mitosis and hyperplasia
atthewoundedgeswithincreasedactivityofMMPs[95].
Continuous synthesis of firm collagen, its stabilization
with cross-linking and the aggregation to thicker bundles
as well as its coordinated orientation, increases the
strength of the reconstruction.
Three months [99] to two years [100] takes “wound
healing”,ifthedurationismeasuredastimeintervalfrom
injury (e.g. during surgery) to accomplishment of the op-
timalandfinalfunctionalresult.Especiallyinadults[101],
the regenerated tissue shows less serous glands [97]
with increased number of excretory ducts [102]. Subepi-
thelial stroma of the regenerated tissue is thicker and
the number of vessels is increased [103]. Only slightly
more than half of all patients show a normal mucociliary
clearance18monthsaftersinussurgeryifevaluatedwith
nuclear medicine techniques [104].
4.7.2 Relevance of matrix Metalloproteinase-9
(MMP-9) as indicator of wound healing
MMP-9belongstothefamilyofmatrixmetalloproteinases,
whichmayactivateeachotherin-vitrosynergistically.This
matrix metalloproteinases is a type IV collagenase and
is also called Gelatinase B [105]. After a stimulus, e.g.
an injury, a 92 kDa proenzyme is released which can be
activated by removal of the propeptide resulting in the
active 82 kDa enzyme [106]. MMP-9 is detectable only
during the first days after injury. Generally, increased
levelsofMMP-9determinedinwoundsecretionareasso-
ciated with problems in reepitheliasation [107], [108].
With regard to sinus surgery, MMP-9 was presented as
predictivemarkerforhealingquality.Highconcentrations
of MMP-9 go together with worse healing quality and
distinct oedema [109].
4.7.3 Risk factors for deteriorated wound
healing
Wound healing is above all, complicated by local distur-
bances like hypoxia [110] or low-nutrition. Systemic dis-
orders (e.g. diabetes mellitus (see below), tumours, im-
mune deficiencies [111], cystic fibrosis, primary ciliary
dyskinesia,aspirinintolerance,bronchialasthma,gastro-
esophageal reflux, autoimmune diseases), cytotoxic or
immunosuppressive medication, allergic disposition or
active or passive smoking [112] may impede wound
healing.
This may result in exceeding granulation tissue, which
favours adhesion formation.
Eosinophilic histology was identified as risk factor for
frontalostiumrestenosisaftertypeIIIdrainageaccording
to Draf [113]. Unfortunately, practical benefit of this
findingislimitedduetothehighfrequencyofeosinophilic
inflammation in chronic sinusitis.
4.8 Rhinologic functional diagnostics
4.8.1 Anterior rhinoscopy
During anterior rhinoscopy, blood vessel pattern and
quality of nasal mucosa with colour and properties of
secretion are evaluated. To facilitate better estimation
of nasal congestion, inspection before and after decon-
gestion is mandatory. Endonasal resistance is assessed
based on configuration and extent of ventilated nasal
areas. Bachmann’s test (introduction of a cotton-tipped
swab in the upper nasal valve) as well as Cottle’s test,
enlarge the area of the nasal isthmus. They are rated as
too unreliable and observer dependent to diagnose isth-
mus stenosis. Visual judgement of the inflow areas has
been recommended [114], but is also observer depen-
dent.
4.8.2 Endoscopy und videoendoscopy
During standardised nasendoscopy, after inspection of
the inferior nasal meatus, the middle nasal meatus with
middle turbinate, the anterior wall of the sphenoid sinus,
sphenoethmoidalrecessusandthesuperiornasalmeatus
with olfactory groove are inspected. As videoendoscopy
[115] digital documentation is possible for analysis by
independent observers [116].
4.8.3 Clinical imaging
The clinical importance of imaging modalities such as
computer tomography (CT) and magnetic resonance
imaging (MRI) lies in the possibility to verify mucosal
swelling of the sinuses [117]. Extent and type of sinusitis
[118], presence of invasive processes such as neoplasia
and invasive fungal sinusitis (MRI: [119]) or non-invasive
fungalsinusitis[120]canbeevaluated.Apositiveaspect
is its high reliability up to a time interval of more than
120 days [121]].
Therelativeimportanceofsonographyislimitedtofollow-
up of acute sinusitis and special problems during preg-
nancy and childhood. Sensitivity and specificity of ultra-
sound of the sinuses is not sufficient for detection of
mucosal swelling in clinical routine [122]. For the same
reason, employment of conventional x-rays in chronic si-
nusitis is discouraged [117].
Innovative studies report a high resolution of optical co-
herence tomography with regard to nasal mucosa [123],
7/24 GMS Current Topics in Otorhinolaryngology - Head and Neck Surgery 2010, Vol. 9, ISSN 1865-1011
Beule: Physiology and pathophysiology of respiratory mucosa ...suggestingthistechniqueasmostinterestingalternative
in future.
4.8.4Diagnostictestsofmucociliaryclearance
in-vivo
Saccharin test
For this most commonly employed global assessment of
mucociliary clearance, saccharin particles (usually a few
crystals) are placed on the head of the inferior turbinate.
Time intervall until the patient reports a sweet gustatoric
sensation is measured. This technically easy and inex-
pensivetestislackinganyside-effect.Itmaybeemployed
in children, but is dependent on a normal sense of taste.
A time interval from placement of saccharin to taste
sensationof≤30min.isregardedasphysiological;atime
interval exceeding one hour as pathological [124]. Re-
peated measurements may vary by about 6 min. [125].
The long duration of this test is commonly regarded as
disadvantagous.Asmodification,applicationofasolution
has been suggested, shortening the transport time to
about 10 min [126].
Nuclear medical tests
Using technetium 99, mucociliary clearance can be
evaluated by means of nuclear medicine [127]. This
sensitive method comes along with increased technical
effort [128] and radioactive contamination, but is due to
its reliability [129] still employed for special questions
[130], [131].
Particle tests
Titanium dioxide (TiO2) is a 500 µm TiO2 particle, which
can be placed on the mucosa to measure its velocity (in
mm/min) in vivo. Standardised reference values have
been reported for the nasal floor, employment is due to
the small weight supposed to be possible on the whole
area of respiratory mucosa. The short duration of this
testisfavourable[132].Inanalogytoearlierstudiesusing
resin [128], [133], this test is believed to particularly
evaluate the gel phase of the nasal mucus. General ad-
vantage of tests employing particles are: independence
of the sense of taste, short duration of testing, and in
some cases less technical effort and less costs.
4.8.5 In-vitro tests for parts of mucociliary
clearance
Ciliary beat frequency (normal range: 7–12 Hz) can be
determined after removal of ciliated cells (e.g. by nasal
curettage or brushing [134]) using a phase-contrast mi-
croscope. An average value for at least four cells should
be calculated when this frequently employed technique
is reported [47], [135]. To increase reliability and allow
for quicker analysis, a specially developed digital photo-
metry has been reported [136].
If a hereditary disorder of cilia function is suspected, cell
culture of ciliated cells has been recommended [137].
This time-consuming technique is only available in very
few centres, but shows nearly ideal sensitivity and spe-
cificity [138].
Ingredientsofnasalmucuscanbeevaluatedin-vitrousing
ELISA [139], [140]. As well, the determination of certain
cytokines is possible in nasal secretions [141]. However
these techniques are not employed in clinical daily
routine.
Mucosal biopsy may be subjected to conventional histo-
logy to aid in differentialdiagnosesand to assessinflam-
matory activity (based on the number of inflammatory
cells). Furthermore, biopsies may facilitate more precise
classification of chronic rhinitis (eosinophil/neutrophil
inflammation).Inaddition,scanningelectronmicroscopy
can be used to visualise the ultrastructural surface of
respiratorymucosaandnasalmucus.Itisnotappropriate
for specific detection of biofilms [142].
Using transmission electron microscopy (TEM), changes
within the cilia going together with altered dynein struc-
tures are reliably detected. Gathering specimens is reli-
ably accomplished by nasal brushing [134]. Costs and
expenditure of time are unfavourable. Furthermore, TEM
is highly specific in detection of biofilms but at the cost
of immense work load [142].
Confocallaserscanningmicroscopy(CLSM)[51]isaless
costlytechniquetodetectbiofilmswithsuperiorsensitivity
andspecificity.ForCLSM,thespecimenisincubatedwith
fluorescentcellmarkers(e.g.Soty9andPropidiumIodide
as differential staining for living and dead cells). After-
wards, it is inspected three dimensionally using a laser
beam. Different wavelengths of the laser stimulate the
cellmarkers,resultingincolouredlightemissiondepend-
ing on the functional state of the cells. Analysing the
surfaceoflargerspecimenscanbeaccomplishedinshort
time and with reasonable workload [51], [143].
4.8.6 Rhinomanometry (RMM)
Rhinomanometry (RMM) allows objective measurement
of nasal airflow synchronous to nasal breathing based
onthetransnasalpressuredifference.Airtightplacement
of a pressure hose at the nostril (e.g. by sticky tape)
elongatesthepressurecolumntothechoanaeandserves
as reference value for the examined contralateral side
[144]. Deformities of the nasal inflow area should be
avoided, due to their associated measurement error. If
measured in accordance to the recommended setting
[144],[145]beforeandafterdecongestion,nasalobstruc-
tion can be rated at a pressure difference of 150 Pa as
flowvelocityorresistance(R=ratioofpressuredifference
and flow velocity; cf. Table 4) [114]. One-sided reference
valuesarediscussedcontroversiallyininternationalliter-
ature[146].Asaconsequence,totalflowof>900ml/sec
at 150 Pa were reported as lower limit of normal [146].
In contrast to classical “anterior RMM“, “posterior RMM“
allows the measurement even in patients with septal
perforation after placement of a pressure hose in the
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mouth, but is prone for measurement errors caused by
positioning of the soft palate in relation to the back wall
of the pharynx.
TherelevanceofRMMinrhinologyhasbeendocumented
[144], but is limited due to missing age-stratified refer-
ence values [147]. Measurement error may reach 15%
[148] and normal rhinomanometry can be obtained in
25%ofpatientswithobviouspathologicalfindings[149].
4.8.7 Rhinoresistometry (RRM)
Employing fluid dynamics, rhinoresistometry is a refine-
ment of rhinomanometry [144], [150]. Measurement
technique and protocol are identical to anterior RMM. To
sum up, nasal resistancecan be classified at a flow velo-
city of 250 cm³/s according to the reference values indi-
cated in Table 5. In addition to the information availably
by RMM, RRM aims at objectively detecting the aetiology
of nasal obstruction. The value of RRM is still discussed
controversially due to missing prospective studies.
Table 5: Classification of unilateral nasal obstruction using
rhinoresistometry [114]
As parameter for the inner width of the nasal cavity and
endonasal friction, hydraulic diameter is indicated. After
decongestion, the hydraulic diameter in a normal nose
shouldmeasure≥6mm.Thisparametercanalsobeused
for objectively evaluating changes in endonasal conges-
tion. [151]. The comparison of a measured and a calcu-
lated graph allows objective assessment of inspiratory
nasal wing collapse. Deviation of both graphs at flow ve-
locities ≥500 cm³/s is regarded as pathological [152].
Endonasalturbulenceis presented as a graph in relation
to flow velocities and calculated as friction coefficient λ
(normal after decongestion λ > 0.025) for both nasal
sides separately.
Measurement process of RRM is reliable [152] and is
aiming to objectively differentiate certain aetiologies of
nasal obstruction (mucosal changes, cartilaginous/bony
findings, pathological inspiratory nasal valve collapse,
changesinendonasalturbulence).Resultsofrhinomano-
metry and rhinoresistometry correlate well [151].
4.8.8 Acoustic rhinometry (AR)
For acoustic rhinometry, sound is applied endonasally
and based on its reflection the dimensions of the nasal
cavityarecalculated.Measurementsshouldbeperformed
under standardised circumstances [144] to secure its
high reliability (measurement error: 2–4% [148], [153]).
Volumeanddiameteroftwotypicallocations,theinternal
isthmus (I-notch [mean cross-sectional area 1; MCA1]
and the head of the inferior turbinate (Conchal notch
[mean cross-sectional area 2; MCA2]) can be calculated
[144], to geometricallydetermineextentandlocalisation
of a stenosis. The nasal diffusor can be measured by the
gain in diameter from I-notch to the the spacious area
posterior to the C-notch [53]. Measurements distal to a
severe stenosis are unreliable [154]. Reference values
have been published for several groups of patients
(Caucasianadults[155],[156],[157]andchildren[156],
[158], [159]; Asian adults [155], [160] and children
[161]).
4.8.9 Long-term rhinoflowmetry (LRM)
Oxygen cannulas are placed in the nostril near the floor
of the nasal vestibule. Nasal airflow can be recorded for
24 hours via a portable device. Graphical presentation
facilitates detailed insight into changes of nasal conges-
tion over time including definition of the type of nasal
cycleandmeasurementofthedurationofworking/resting
phase [54], [64]. The aim is to objectively assess patho-
logical mucosal swelling under conditions of daily living
[64].
4.8.10 Measurement of nasal expiratory nitric
oxide (NO)
Human cells produce nitric oxide (NO) from arginine by
theenzymesNO-synthases[162].Nitricoxideisproduced
in the nasal cavity [162], but first and foremost in the
paranasal sinuses [162]. It has anti-bacterial, as well as
anti-viral properties and regulates mucociliary clearance
viacontrolofnasalsecretions[163],[164].Measurement
of nasal NO [in parts per million; ppm] is influenced by
lower airways [165], local and systemic diseases and
their therapy [166], compliance [167], nasal cycle [168],
anatomy [169] and technical aspects [170]. Valid mea-
surement protocols have been reported [171] for compli-
ant patients [169] and infants [172]. Reliable reference
values do not exist due to high interindividual variation
[173].
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rhinosinusitiswithpolypscanbedistinguishedfromthose
without polyps or healthy controls [174] and treatment
effects can be monitored [175]. Most significant differ-
encestoanormalpopulationcanbeobtainedinpatients
with primary ciliary dyskinesia or cystic fibrosis [176],
suggesting nasal NO as non-invasive screening tool for
these diseases [177].
4.9 Special aspects to functions of
respiratory mucosa
4.9.1 Particularities of children
Children in Western industrial nations suffer from 6–8
viral upper airway infections per year [178] with 5–13%
developingbacterialsinusitis[179],[180].Thisfrequency,
together with the common problems of adenoid hyper-
plasiafavouringnasalblockageandsusceptibilitytolocal
inflammation, complicate effective diagnosis of chronic
rhinitis.Noepidemiologicaldataisavailablefornon-aller-
gic chronic rhinitis in children. In newborn and infants, a
connatal hypothyroidism, a (usually autoimmune) thyre-
oiditis [181], or an infection with Chlamydia (usually ac-
quired during birth) may results in symptoms of nasal
obstruction [182]. Children, whose mother is heroin ad-
dicted, show nasal complaints often due to structural
changes of cilia [183]. In children below the age of 12,
a sweat test is mandatory to exclude cystic fibrosis in
case endonasal polypoid tissue [184]. If simultaneously
chronic bronchitis, sinusitis and otitis are present, a
primary ciliary dyskinesia (immotile ciliary syndrome) or
Kartagenersyndromeshouldbetakenintoconsideration
[184].
In infants suffering from recurrent infections, (humoral)
immunodeficiencies should be taken into account. With
an incidence of 1:700 Ig-A deficiencies due to a B-cell-
defect are most often diagnosed [185]. Besides, there
exists evidence that in children gastroesophageal reflux
is an confoundingfactor for recurrentupper airway infec-
tions[186].Duringpuberty,sexuallytransmitteddiseases
[187](e.g.syphilis[188])andhormonalfluctuationsmay
result in rhinologic functional disturbances [189].
For diagnostics in and follow-up of paediatric patients,
acoustic rhinometry is recommended. Growth-induced
increase of airflow or decrease of resistance measured
with rhinomanometry can be estimated by comparison
with body weight development. Using this technique,
pathophysiological effects can be distinguished from
growth-induced ones.
4.9.2 Particularities of geriatric patients
During aging, nasal mucosa shows signs of atrophy with
decrease of goblet cells and thickening of the basal
membrane [190]. This repair is mirrored in increased
expression of caspase-3, an apoptotic marker [191]. In
parallel, elasticity of nasal mucosa decreases, by part
due to a decreasing level of oestrogen. Accordingly, in
postmenopausalwomen,substitutionusinganasalspray
has been recommended [192], [193].
Resultsontheeffectofageonmucociliaryclearanceare
contradicting: While some studies showed no effect on
mucociliary clearance [194], [195], others were able to
demonstrate a decrease of ciliary beat frequency with
increaseofsaccharintransittimeasequivalentofdeteri-
orationofmucociliaryclearanceinoldage[196].Viscosity
of nasal secretion increases and causes post nasal drip
with consecutive repeated clearing of the throat.
As structural change of respiratory mucosa in old age,
single instead of double tubules were detected using
transmission electron microscopy. In rhinoscopy, a wide
nasalcavitywithquitedrynasalmucosaliningistypically
seen.Increasedturbulencedespiteobjectivelyfreenasal
passages may result in a feeling of nasal obstruction
(paradoxical nasal blockage). Accordingly, endonasal
volumeandareasofMCA1andMCA2areenlarged[197].
Prevalenceofendonasalpolypsincreaseswithage[198].
Also, primary atrophic rhinitis is associated with aging
[199].Duetothefrequentmedicationwithmultipledrugs,
rhinitismedicamentosahasahighrelevanceasdifferen-
tial diagnosis [199], [200]. As therapy, topical steroids
(sometimes under addition of propylene glycole), expec-
torant drugs to stimulate exocrine glands and nasal
douching with saline are recommended [184].
4.9.3 Influence of diabetes mellitus on the
respiratory function
In diabetics, upper airway infections do not occur more
frequently than in healthy subjects [201]. There exists
controversial discussion whether the diabetic nose is
more frequently colonised by pathogens, such as S.
aureus [202].
Much clearer is the situation in diabetics undergoing
dialysis: These have in 53.4% (non-diabetics: 18.6%) a
nasal colonisation with methicillin-sensible and in 19%
withmethicillin-resistantS.aureus(MRSA;non-diabetics:
6.0%). In addition, if a patient has a central-venous
catheter, his risk of endonasal colonisation of S. aureus
is 35 times increased in comparison to patients with ar-
terio-venous fistula [203].
A polymorphism of vitamine D receptor in diabetics has
alsobeenassociatedwithcolonisationofS.aureus[204].
Moreover, concentration of the bactericidal nasal NO is
decreased in insulin dependent diabetes mellitus [166].
In parallel, diabetics have an increased resistance
measured by RMM. This increase is more pronounced
beforethanafterdecongestion,indicatingachronicstate
of increased congestion.
Chronic congestion is also favoured by mucociliary
clearance, the latter being reduced in diabetics [205],
[206] due to alcalised pH-values of nasal secretions
[207]. Insulin-dependent diabetes mellitus and diabetes
lastingformorethantenyearsresultinfurtherdeteriora-
tion of mucociliary clearance [207].
Diabetics have more frequent clinical signs of a dry nose
[208] and are at a higher risk to suffer from non-invasive
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[209] or invasive [210] fungal sinusitis [211]. A topical
moisteningby employmentofnasaldouchingandoilhas
been recommended as therapy or prophylaxis, respec-
tively [208].
4.9.4Nasalrespiratorymucosaasareaofdrug
application
If topical drug application is discussed, it is of special
importance to distinguish pharmacokinetics and phar-
macodynamics. The pharmacokinetic science describes
effects of the human body on the drug, while pharmaco-
dynamics aims at studying the effect of the drug on the
human body. In the following, special pharmacokinetic
aspects are elaborated on.
Distribution of drugs in the nose and the paranasal
sinuses
Use of nasal spray transports only a small part of the
dosage to the paranasal sinuses, while the biggest part
is deposited in the inferior meatus and on the head of
the inferior turbinate [212]. For optimal application with
regard to the frontal sinus, Vertex-to floor position has
been recommended[213]. Effectivity of dexamethasone
nasal drops in this position has been demonstrated with
prevention of frontal ostium restenosis [214]. Unfortu-
nately, compliance to employ this position is limited by
existing co-morbidities (e.g. diseases of the cervical
spine). In contrast, inhalation devices using alternating
pressure waves reach the paranasal sinuses reliably
within three minutes near the ostium [215].
Another application form is nasal douching being well-
tolerated by 80% of patients. To rinse a paranasal sinus
effectively, an ostium with a diameter of 3.95 mm is ne-
cessary[216].Postoperatively,nasaldoucheisareliable
mode of application [215], [217]. To rinse the frontal si-
nus,amaximalforwardbending(“Vertextofloor-position“)
with maximal volume of the employed squeeze bottle is
recommended. Generally, nasal douching should be
performed with high volume and low pressure [218].
An additional innovative method of topical therapy is the
employment of drug-releasing stents [219]. Releasing
dexamethasone, granulation formation [96] and osteo-
neogenese [93] are decreased significantly, without im-
peding reepithelialisation. While stents may provoke a
local foreign body reaction with biofilm formation, they
can reliably provide topical application to inaccessible
areas of the upper airways.
Aspects regarding resorption and absorption of
medication in nose and sinuses
Mucociliary clearance limits the dosage of topically ap-
plied drugs (cf. Figure 2). Particle transport of MCC re-
stricts application duration of topical medication to an
estimated20–30min.[220],[221].Inaddition,mechan-
ical activity of cilia destroys drug molecules [37], [220].
Moreover, nasal mucus is a barrier to diffusion [222],
[223]. Molecularsizeandelectricchargearedecisivefor
thediffusioncapacityofadrug[222],[224].Withregards
to this background, microemulsions were developed to
increase resorption into nasal mucus [225].
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theirabsorptionproperties.Thismaybetakenadvantage
ofbysupplyoflipophilpro-formsoftheactivesubstances
[226]. Alternatively, medication influences mucin secre-
tion [227] and it viscosity [228]. For drugs interacting
with glycoproteins of nasal mucus [229], this property
may limit drug permeation [230]. Especially charged
particles with the capacity to build hydrogen bonds and
lipophil particles are affected [231].
Nasal mucosa is well permeable for hydrophilic sub-
stances and lipophilic ones below a molecular mass of
1000Da[232],[233],becausethenasalmembranehas
pores with dimensions of 3.9 to 8.4 Å. Transcellular
transport is possible for lipophil substances, while
chargedhydrophilicdrugsaremainlytransportedparacel-
lularly [234]. Paracellular transport happens via tight
junctions(TJ)orthezonulaoccludens(ZO)[234].Connec-
tionsbetweengobletcellsorgobletcellsandciliatedcells
are rated as loose [234], [235]. Besides, they show a
high variation of permeability [236]. Many substances
are inactivated by the high enzymaticactivity(local”first-
pass effect“) of nasal mucosa during the process of ab-
sorption [234]. Carrier systems (e.g. chitosan [135],
[237]), are employed to enhance nasal bioavailability. In
parallel, a strategy has recently been developed to intra-
operatively employ resorbable, medication-releasing ap-
plication systems to increase the applicated dosage.
Possiblities of technical refinement of modified systems
are limited, as mucosal function should not be harmed.
Nasal drugs have to be well tolerated, exert beneficial
effect on ciliary function and if applicable should show
good dispensing properties (if applicated as nasal spray)
and/or a high degree of adhesion (for better resorption).
5 Chronic rhinitis – selected
disorders
In the following section, selected typical forms of chronic
rhinitis will be discussed.Allergicrhinitis is differentiated
from non-allergic forms. 57% of patients with chronic
rhinitissufferfromanon-allergicform[238].Classification
of non-allergic rhinitis is still controversially discussed
and quite complex [184]. Some non-allergic, non-infec-
tious forms of rhinitis with a pathophysiology closely
connected to nasal respiratory mucosa are summarised
here. With regards to different non-allergic forms, it is
referredtotwoelaborativeandrecentpublications[184],
[239].
5.1 Rhinitis medicamentosa
Rhinitismedicamentosa,alsocalleddrug-inducedrhinitis,
isdefinedaspathologicalcongestionorthenasalmucosa
with nasal blockage, nasal drainage (anterior rhinorrhea
and post nasal drip) and optional sneezing. It occurs as
a direct consequence of drug intake, with the classical
disorder developing after prolonged use of decongesting
nasal drops [240]. Due to its high prevalence, rhinitis
medicamentosa is of special significance among the
various subtypes of non-allergic rhinitis. Incidence is es-
timatedas6–9%inpatientswithnasalobstruction[241],
[242] and 1–7% [241] of unselected patients in an ENT
office.
Reported drugs that may possibly cause rhinitis medica-
mentosa (cf. Table 6) belong to various groups of drugs.
In 1931, this disorder was first reported by Fox [243]. As
pathophysiology, respiratory mucosa becomes accus-
tomedtothedrug,withthelatterresultinginminor[244]
and shorter [245] drug-induced effect (hyporeactivity). It
remainsunknownwhetherthisisaconsequenceoftissue
hypoxia with reactive hyperaemia due to vasodilatation
[246], a negative presynaptic feedback mechanism at
α-2-receptors[247],and/orchangeofvasomotorictonus
byincreasedactivityofcholinesterase[248],[249].Based
on structural deformities, increased permeability [250]
and secretion of glands [251] were reported.
The risk to suffer from rhinitis medicamentosa is gender
independent and it most commonly affects middle aged
adults.Thepostulatedincreasedsusceptibilityofpatients
with chronic inflammation of nasal respiratory mucosa
[252] failed to be proven [253]. The risk to acquire this
diseasedramaticallyincreasesiftopicalsympathomimet-
ics are applied three times a day for more than 10 days
[245], [253], [254] or night-time application exceeds 4
weeks [245], [255].
Decongestants used to have benzalkonium chloride as
a preservative. This quartery ammonium compound is
capable of destroying cell walls of microorganisms. In-
vitro, toxic effects on cilia [252], deterioration of
granulocyte chemotaxis and phagocytosis [256] and of
neutrophil defense [257] have been reported. Because
benzalkoniumchlorideaidsdevelopmentofdrug-induced
rhinitis [253], [258], aggravates its symptoms [241],
[259] and may provoke rhinitis medicamentosa if used
alone [260], only a few formulations in Europe are still
available containing benzalkonium chloride [240].
Structural changes in rhinitis medicamentosa include
damage and loss of cilia [261], metaplasia [261] and
epithelial oedema [262], tears in the basal membrane
[261]andopeningsinsubepithelialendothel[250],[261]
togetherwithvasodilatation[241].Moreover,hyperplasia
ofgobletcells[251],[262]andinfiltrationofinflammatory
cells [263] were demonstrated probably as equivalent of
reparativechangeswithincreasedexpressionofepithelial
growth factor [263]. As complication, septal perforation
may occur [264]. If not adequately treated, this disease
leads to secondary atrophic rhinitis up to frank clinical
picture of ozaena [265].
Carefulhistorytakingwithquestionsregardinglasttopical
and complete current medication is the key element to
diagnose this disorder. For therapy planning, detailed
history of previously unsuccessful therapeutic trials is
helpful. Clinical examination should be performed in the
early morning to provide the typical clinical picture with
congested nasal mucosa in nasendoscopy after last top-
ical medication on the previous evening [241]. Nasendo-
scopy is also beneficial to detect structural changes,
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which eventually may have led to the use of nasal drops.
For apparative diagnostics, anterior rhinomanometry,
acoustic rhinometry and measurement of mucociliary
function have been recommended [266].
For successful therapy, identification and elimination of
the causative drug is decisive. The patient has to be in-
formed of the underlying pathophysiology to improve
compliance (“counselling”) [267]. Sudden stop of intake
leads to a rebound-swelling. In severe cases, separate
cessationofapplicationonbothnasalsidesismandatory.
Topical application of steroids (in severe cases starting
before cessation of the causative agent) is able to effec-
tively diminish rebound-swelling [268], [269]. Onset of
decongestive effect is expected 4–7 days after start of
steroiduse[262].Asurgicalprocedurelikeaturbinoplasty
may ease withdrawal for the patient (reported success
rate of 88% for laser turbinoplasty [270]), but will not
cure the disease. After repeated turbinoplasty due to
prolonged abuse of decongestants, a surgically caused
nasaldrynessmaydevelop.Thereforeathreemonthtime
interval between cessation of abuse and surgical correc-
tion has been recommended [241].
Thenecessitytodiagnoseandpossiblytreattheunderly-
ingpathology,initiallyleadingtoabuseofdecongestants,
isnottobeunderestimated[241].Theunderlyingdisorder
fortopicalmedicationresultinginrhinitismedicamentosa
is in 30% of cases an episode of upper respiratory tract
infection, in 22% a non-allergic,non-infectiousrhinitis, in
16% allergic rhinitis, in 30% structural deformities (such
as septal deviation, endonasal polyps, posttraumatic
pathologies), and in 3% hormonal changes [271].
For prevention, avoidance of benzalkonium chloride is
mandatory [259]. Patients have to be aware of their per-
sistent susceptibility to develop relapse of rhinitis
medicamentosa even one year after onset of successful
treatment [272]. Furthermore, control visits every three
monthshavebeenrecommended.Duringinfection,short-
term use (up to 3 days) of nasal decongestants at lower
concentrations may present a preventive strategy.
5.2 Atrophic rhinitis, anterior rhinitis
sicca and ozaena
Atrophic rhinopathy is characterised as a chronic inflam-
mationofunclearaetiology,leadingtoatrophyanddecay
oftheentireendonasalmucosaandtheunderlyingbone.
Aprimaryform,foremostoccurringindevelopingcountries
andshowingspontaneousdevelopment,isdistinguished
from a secondary form after rhinologic surgical proce-
dures (especially: turbinoplasty), trauma, infection,
granulomatous inflammation, or radiation [273]. For the
primary form, six times more females than males are af-
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more often in rural areas than in urban ones [274]. A
genetic component has been reported [275] with inci-
dencedecreasinginrecentyears[276].Aveteneriantype
ofprimary atrophicrhinitisis oftenseenin pigs, resulting
in development of multiple veterinary vaccines against
the causative pasteurella multocida toxin [277].
Endonasal crust formation (usually on the middle turbin-
ate), epithelial metaplasia with loss of cilia and superin-
fection of nasal mucosa (with detection of Klebsiella
ocaenain65–100%[274],[278])arevisible.Inaddition,
vasodilatation [274] and changes in bone formation in-
cluding osteitis of the turbinate bony may occur [278].
As a consequence, MCA1 is enlarged [279]. A classical
smelldevelopsandpolypformation,chronicdacryocystitis
[280], scar-induced stenosis of the choanae [281], or
pharyngitis sicca [282] are possible. The endpoint of
atrophicrhinitisiscalledozaena('stink-polyp').Thepatient
doesnotrealisehisodour,butcomplaintsaboutanosmia
[283].
Histologically, increased activity of caspace-3 in the epi-
theliumandsubepithelialglandshasbeendemonstrated
as indicator for apoptosis [284]. Absolute quantity and
chemical quality of phospholipids (with surfactant) is de-
creased [285]. Therefore, a lack of surfactant has been
suspectedasaetiopathogenesisofatrophicrhinitis[285].
Byapplicationofangiogeneticinhibitors,asimilardisorder
can be provoked in a recently reported animal model
[286].
Anterior rhinitis sicca is not easily distinguished from
atrophicrhinitis,butaffectsonlythemucosaoftheanteri-
or septum with elsewhere in the nasal cavity presenting
normally configurated mucosa. In case of perichondritis,
ulcer formation up to septal perforation may occur. Pa-
tients report of nasal dryness, itchiness and crust forma-
tion.Aetiologyis unknown. Physical,chemical(e.g. snuff,
cocaine),andmechanicalirritation(digitalmanipulation)
are discussed.
Based on a progressively deteriorated mucociliary clear-
ance, differentiation of rhinitis sicca to atrophic rhinitis
is possible. For diagnosis, endoscopy, histological and
microbiological examination, imaging and allergy tests
aremandatory[273],because60%haveasinusitis[274]
and 85% an allergic disposition. Endonasal resistance if
belownormal,whichiscalled”paradoxicalnasalobstruc-
tion“ in case of subjective nasal blockage [273]. At a
sensitivity of 95% (specificity: 77%) an atrophic rhinitis
isdiagnosed,ifthepatient’ssuffersfromchronicsinusitis
for more than six months and shows an additional two
out of five features. These include: nasal bleeding,
anosmia,purulentrhinorrhea,chronicupperairwayinfec-
tion, and having had two or more sinus surgeries [287].
Nexttoaninfectiousaetiology(duetoKlebsiellaozaenae
andBacillusfoetidus[273],[282]),environmental,endo-
crinologic and allergic-immunologic causes have been
suspected [274], [282]. Atrophic rhinitis occurs more
commonlyneardesserts[282]inpatientswitharelatively
wide nasal cavity [288]. In parallel, surgical procedures
narrowing the nose (up to its closure) cure the disease.
From this background, disturbance of endonasal airflow
wasestimatedasunderlyingpathophysiology.Accordingly,
atrophic rhinitis was called a consequence of nasal cycle
deterioration [289], [290].
With regards to treatment, no prospective controlled
studies have been reported [291]. Empiric conservative
treatment consists of local application of dexpanthenol
andoiltoresolvethecrustsandtostimulatetheregener-
ationofnasalmucosa.Sesameandsojaoilimproveciliary
beat frequency in contrast to essential oils [292]. Addi-
tional nasal douching, occasionally under supplementa-
tion of glucose (up to 25%), sole inhalation and sleeping
next to an opened window have been recommended
[293]. Antibiotics (rifampicin: [294]) have been used in
caseofpurulentsecretion[295] orasadjuncttosurgical
procedures (aminoglycoside: [296]), without being able
to cure the disease [273]. Even closure of the nostrils
e.g. by an obturator, has been suggested [297].
5.3 Vasomotor rhinitis
Vasomotor rhinitis (also called: hyperreflectoric rhinitis)
is a disorder diagnosed by exclusion. Among non-allergic
rhinitis, this subgroup is most common, affecting 60% of
patients [298]. Aetiology is unclear with both episodical
and perennial clinical manifestations occurring. A
cholinergic course, going together with increased nasal
secretion ('Runner'), can be distinguished from a clinical
course characterised by nasal obstruction ('Blocker')
mediated by nociceptive nerve fibre.
Reported trigger mechanisms include cold air [299],
change of temperature, food (spices, alcohol), physical
activity, smoke, dust and automobile exhaust.
Histologically, a strong expression of NO-synthetase is
detected in subepithelial smooth muscle cells of the
cavernous sinus [300]. Moreover, intense staining with
3-Nitrotyrosin, a product of NO-metabolism [300]. SP,
CGRP, and VIP are increased, while IL-12 is diminished.
Eosinophilicfindings contradictthe presenceof vasomo-
tor rhinitis [291].
A missing change of endonasal resistance after applica-
tion of oxymetazoline supports diagnostically the hypo-
thesis of etiologic changed autonomic innervation [301]
and is helpful for posing the diagnosis. Measurements
of heart frequency show a relative, parasympathetic hy-
perreactivity [302]. Based on standardised question-
naires, void of symptoms in spring and in presence of
cats, missing allergic diseases of the parents, symptoms
associated with perfumes and scents and age of first
manifestationshowapredicativevalueforsufferingfrom
vasomotor rhinitis [303].
Topical antihistamines [304], glucocorticoids [305] and
ipatropiumbromideareveryeffectiveintreatingvasomo-
tor rhinitis [298]. Interestingly, in a subgroup with com-
plaints triggered by wind and change of temperature,
Fluticasone treatment showed no significant benefit
[306]. Locally injected botulinum toxine (I0 international
units) improves subjective complaints of patients with
vasomotor rhinitis for eight weeks [307]. Vidian neurec-
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symptoms in 80% of patients. Acupuncture used in a
placebo-controlled phase III study, showed a positive ef-
fect on a nasal symptom score [308].
6 Conclusion
Respiratory mucosa of the nose and paranasal sinuses
exertsvariousfunctions,withtheircomplexmorphological
and functional correlations becoming increasingly well
understood.
Derangement of the respiratory function is one of the
most frequent disorders of human beings. Due to avail-
able treatments with antibiotics and effective topical
steroids, frequency of disorders is changing. Previously
less common subtypes of chronic rhinitis gain increased
importance. To encourage detailed pathophysiological
understanding, selected disorders have been presented
with their treatment options.
Earlydiagnosticsanddifferentiatedtreatmentcanprevent
continuous loss of function and development of consec-
utive disorders. This may help to avoid increased treat-
ment costs. In this way, diagnosis and therapy of respira-
tory function gain next to their inherent individual impor-
tanceincreasedrelevancefromtheperspectiveofsociety.
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